CCIA
SMMT icon

Campbell & Co Investment Adviser’s Summit Therapeutics SMMT Stock Holding History

Campbell & Co Investment Adviser’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,407
Closed -$269K – 1391
2025
Q4 		$269K Buy
+15,407
New +$290K 0.01% 998

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Campbell & Co Investment Adviser's SMMT Position: Q1 2026 in Review

Campbell & Co Investment Adviser sold out of Summit Therapeutics (SMMT) in Q1 2026, closing a stake of 15,407 shares — an estimated $269K sold.

Campbell & Co Investment Adviser first reported a position in SMMT in Q4 2025 and held it in 1 quarter. The position peaked at $269K in Q4 2025. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • Campbell & Co Investment Adviser reported no remaining Summit Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 15,407 Summit Therapeutics shares in Q1 2026, an estimated $269K.
  • Campbell & Co Investment Adviser first reported a position in Summit Therapeutics in Q4 2025 and held it in 1 quarter.
  • Campbell & Co Investment Adviser's Summit Therapeutics position peaked at $269K in Q4 2025.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.